These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26433554)

  • 21. Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.
    Truitt G; Gittleman H; Leece R; Ostrom QT; Kruchko C; Armstrong TS; Gilbert MR; Barnholtz-Sloan JS
    J Neurooncol; 2019 Aug; 144(1):53-63. PubMed ID: 31209773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Challenges for clinical research on rare tumors in Europe].
    Blay JY
    Bull Acad Natl Med; 2013 Jan; 197(1):103-21; discussion 121-2. PubMed ID: 24672983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Children's Oncology Group's 2013 blueprint for research: rare tumors.
    Rodriguez-Galindo C; Krailo M; Frazier L; Chintagumpala M; Amatruda J; Katzenstein H; Malogolowkin M; Spector L; Pashankar F; Meyers R; Tomlinson G;
    Pediatr Blood Cancer; 2013 Jun; 60(6):1016-21. PubMed ID: 23255219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A patient-researcher partnership for rare cancer research.
    Staniszewka S
    Nat Med; 2020 Feb; 26(2):164-165. PubMed ID: 32042195
    [No Abstract]   [Full Text] [Related]  

  • 26. Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers.
    Walczak A; Patterson P; Thomas D
    Med J Aust; 2018 Oct; 209(8):330-332. PubMed ID: 30309304
    [No Abstract]   [Full Text] [Related]  

  • 27. Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation.
    Mathoulin-Pélissier S; Pritchard-Jones K
    Eur J Surg Oncol; 2019 Jan; 45(1):22-30. PubMed ID: 29526369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.
    Deverka PA; Bangs R; Kreizenbeck K; Delaney DM; Hershman DL; Blanke CD; Ramsey SD
    J Natl Cancer Inst; 2018 Jun; 110(6):553-559. PubMed ID: 29684151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should clinical trials be approached differently for rare cancers?
    Olver I
    Future Oncol; 2016 May; 12(10):1207-9. PubMed ID: 26939845
    [No Abstract]   [Full Text] [Related]  

  • 30. Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute.
    Szczepanek CM; Hurley P; Good MJ; Denicoff A; Willenberg K; Dawson C; Kurbegov D
    J Oncol Pract; 2017 Jun; 13(6):395-400. PubMed ID: 28481681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
    Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
    BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Launching a plan for the Cancer Moonshot.
    The Lancet
    Lancet; 2016 Sep; 388(10050):1130. PubMed ID: 27650078
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving treatment results with reference centres for rare cancers: where do we stand?
    Ray-Coquard I; Pujade Lauraine E; Le Cesne A; Pautier P; Vacher Lavenue MC; Trama A; Casali P; Coindre JM; Blay JY
    Eur J Cancer; 2017 May; 77():90-98. PubMed ID: 28384534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report.
    Bertagnolli MM; Blanke CD; Curran WJ; Hawkins DS; Mannel RS; O'Dwyer PJ; Schnall MD; Wolmark N
    Cancer; 2020 Dec; 126(23):5022-5029. PubMed ID: 32970346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
    Ray-Coquard I; Trama A; Seckl MJ; Fotopoulou C; Pautier P; Pignata S; Kristensen G; Mangili G; Falconer H; Massuger L; Sehouli J; Pujade-Lauraine E; Lorusso D; Amant F; Rokkones E; Vergote I; Ledermann JA;
    Eur J Surg Oncol; 2019 Jan; 45(1):67-74. PubMed ID: 29108961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Publicly funded clinical trials and the future of cancer care.
    Schilsky RL
    Oncologist; 2013; 18(2):232-8. PubMed ID: 23363807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for the design of small population clinical trials.
    Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
    Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers.
    Thavaneswaran S; Sebastian L; Ballinger M; Best M; Hess D; Lee CK; Sjoquist KM; Hague WE; Butow PN; Simes RJ; Thomas D
    Med J Aust; 2018 Oct; 209(8):354-355. PubMed ID: 30138578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.